IQVIA Holdings Inc: Takeaways from our fireside chat with IQV at 2026 BofA Healthcare Conference

Research evidence excerpt

IQVIA Holdings Inc: Takeaways from our fireside chat with IQV at 2026 BofA Healthcare Conference

Accessible version

IQVIA Holdings Inc

Takeaways from our fireside chat with IQV

at 2026 BofA Healthcare Conference

Maintain Rating: BUY | PO: 245.00 USD | Price: 172.38 USD

Fireside chat with CFO 13 May 2026

We hosted IQVIA’s (IQV) Mike Fedock (CFO) for a fireside chat. Much of the conversation Equity

was centered on 1Q performance, R&DS demand/bookings, AI adoption across clinical

Michael Ryskin

and commercial workflows, margin dynamics, and capital deployment. Mgmt. reiterated Research Analyst

confidence in the FY outlook, emphasizing strong 1Q execution, healthy demand metrics, BofAS +1 646 855 4373

and AI as a tailwind rather than a risk. We came away constructive and maintain our Buy michael.ryskin@bofa.com

rating. Avantika Dhabaria

Research Analyst

1Q beat supports confidence; B2B noise largely PT driven BofAS+1 646 743 0170

Mgmt. was pleased with 1Q, with revenue and EPS above the high end of expectations avantika.dhabaria@bofa.com

and organic growth accelerating in both Commercial Solutions and R&DS. R&DS Alexa Chan Research Analyst

delivered ~$2.5bn of net bookings with double-digit yoy growth, while the 1.04x B2B BofAS

was impacted by lower pass-through bookings, which management characterized as an +1alexa.chan@bofa.com646 855 5636

idiosyncratic mix issue rather than a change in client strategy, therapeutics or AI-related

demand.

Demand constructive; EBP funding not fully reflected Stock Data

Mgmt. highlighted strong EBP funding trends, with 1Q funding nearly doubling yoy and Price 172.38 USD

April funding up ~400% yoy. That said, mgmt. believes its recent EBP success is more Price Objective 245.00 USD